| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: AMEV |
| Security Type |
Common Stock |
| Lead Underwriter |
CIBC World Markets Inc |
| Days In Registration |
75 |
| Date Filed |
12-May-2000 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2009) |
| Industry |
Manufacturing |
| Business Description |
Biotechnology company, focusing on medical research and in vitro and in vivo diagnostic services |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
22.1M |
| President and CEO |
William D. Huse, M.D., Ph.D |
| Number of Employees |
106 |
|
| Original Filing Information |
| US |
| Shares Filed |
3.75M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
3.75M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
697.5K |
| File Amount |
$60.0M |
| File Price Range |
$17.00 - $15.00 |
| File Mid Price |
$16.00 |
Current Filing Information
(Amended 26-Jul-2000) |
|
US |
|
Shares Filed |
3.75M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
3.75M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$60.0M |
| · % Change from Original |
0.0 |
| File Price Range |
$17.00 - $15.00 |
| File Mid Price |
$16.00 |
|
